# Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women

> **NCT02400567** · PHASE2 · COMPLETED · sponsor: **UNICANCER** · enrollment: 125 (actual)

## Conditions studied

- Neoadjuvant Operable Breast Cancer

## Interventions

- **DRUG:** Fluorouracile
- **DRUG:** Epirubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Letrozole
- **DRUG:** Palbociclib

## Key facts

- **NCT ID:** NCT02400567
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2018-01
- **Final completion:** 2020-09
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2022-03-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02400567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02400567, "Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02400567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*